A clear patency benefit of a drug-eluting stent (DES) over bare metal stents (BMSs) for treating peripheral artery disease of the femoropopliteal segment has not been definitively demonstrated. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results